Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gleave

Showing results (681-690 of 839) with videos related to

Pageof 84
Sort By:
Oncogene|September 9, 2018
A molecular portrait of epithelial-mesenchymal plasticity in prostate cancer associated with clinical outcomeNataly Stylianou, Melanie L Lehman, Chenwei Wang, et al.
The Journal of Urology|August 5, 2018
Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASSJames T Kearns, Anna V Faino, Jeanette M Schenk, et al.
JAMA Oncology|August 28, 2020
Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk StabilityMatthew R Cooperberg, Yingye Zheng, Anna V Faino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 24, 2020
HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studiesD J Khalaf, I M Aragón, M Annala, et al.
Molecular Cancer Therapeutics|August 5, 2017
Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin InteractionsKush Dalal, Meixia Che, Nanette S Que, et al.
Scientific Data|July 17, 2019
Analysis-ready datasets for insecticide resistance phenotype and genotype frequency in African malaria vectorsCatherine L Moyes, Antoinette Wiebe, Katherine Gleave, et al.
Bioorganic & Medicinal Chemistry Letters|October 12, 2010
Identification of 2-oxo-N-(phenylmethyl)-4-imidazolidinecarboxamide antagonists of the P2X(7) receptorLee Abberley, Aude Bebius, Paul J Beswick, et al.
European Urology|February 14, 2018
Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance OutcomesMatthew R Cooperberg, James D Brooks, Anna V Faino, et al.
Oncotarget|February 22, 2018
Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancerDebashis Sahoo, Wei Wei, Heidi Auman, et al.
Cancer Discovery|October 28, 2016
The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate CancerJennifer L Bishop, Daksh Thaper, Sepideh Vahid, et al.
Pageof 84

Showing results (681-690 of 839) with videos related to

Sort By:
Pageof 84
Oncogene|September 9, 2018
A molecular portrait of epithelial-mesenchymal plasticity in prostate cancer associated with clinical outcomeNataly Stylianou, Melanie L Lehman, Chenwei Wang, et al.
The Journal of Urology|August 5, 2018
Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASSJames T Kearns, Anna V Faino, Jeanette M Schenk, et al.
JAMA Oncology|August 28, 2020
Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk StabilityMatthew R Cooperberg, Yingye Zheng, Anna V Faino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 24, 2020
HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studiesD J Khalaf, I M Aragón, M Annala, et al.
Molecular Cancer Therapeutics|August 5, 2017
Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin InteractionsKush Dalal, Meixia Che, Nanette S Que, et al.
Scientific Data|July 17, 2019
Analysis-ready datasets for insecticide resistance phenotype and genotype frequency in African malaria vectorsCatherine L Moyes, Antoinette Wiebe, Katherine Gleave, et al.
Bioorganic & Medicinal Chemistry Letters|October 12, 2010
Identification of 2-oxo-N-(phenylmethyl)-4-imidazolidinecarboxamide antagonists of the P2X(7) receptorLee Abberley, Aude Bebius, Paul J Beswick, et al.
European Urology|February 14, 2018
Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance OutcomesMatthew R Cooperberg, James D Brooks, Anna V Faino, et al.
Oncotarget|February 22, 2018
Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancerDebashis Sahoo, Wei Wei, Heidi Auman, et al.
Cancer Discovery|October 28, 2016
The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate CancerJennifer L Bishop, Daksh Thaper, Sepideh Vahid, et al.
Pageof 84